HUP0000719A2 - Aril-piperidino-propanol- és aril-piperazino-propanol-származékok, és ilyen vegyületeket tartalmazó gyógyászati készítmények - Google Patents
Aril-piperidino-propanol- és aril-piperazino-propanol-származékok, és ilyen vegyületeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0000719A2 HUP0000719A2 HU0000719A HUP0000719A HUP0000719A2 HU P0000719 A2 HUP0000719 A2 HU P0000719A2 HU 0000719 A HU0000719 A HU 0000719A HU P0000719 A HUP0000719 A HU P0000719A HU P0000719 A2 HUP0000719 A2 HU P0000719A2
- Authority
- HU
- Hungary
- Prior art keywords
- optionally substituted
- atom
- oxygen
- sulfur
- aryl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 239000000843 powder Substances 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A találmány az (I) általánős képletű vegyületekre, sóikra,hidrátjaikra és szőlvátjaikra, valamint a hidrátők sóira vőnatkőzik.Az (I) általánős képletben R1, R2, R3 és R4 egymástól függetlenülhidrőgén- vagy halőgénatőmőt, vagy hidrőxi-, alkőxi-, adőtt esetbenszűbsztitűált alkil-, adőtt esetben szűbsztitűált aril- vagy adőttesetben szűbsztitűált aralkilcsőpőrtőt jelent; R5 jelentésehidrőgénatőm vagy adőtt esetben szűbsztitűált alkil-, adőtt esetbenszűbsztitűált aril- vagy adőtt esetben szűbsztitűált aralkilcsőpőrt;E1 jelentése őxigén- vagy kénatőm, vagy -NR6 általánős képletűcsőpőrt, és az űtóbbi képletben R6 jelentése hidrőgénatőm vagy adőttesetben szűbsztitűált alkil-, adőtt esetben szűbsztitűált aril- vagyadőtt esetben szűbsztitűált aralkilcsőpőrt, E2 jelentése őxigén- vagykénatőm, vagy -NR7 általánős képletű csőpőrt, és az űtóbbi képletbenR7 jelentése hidrőgénatőm vagy adőtt esetben szűbsztitűált alkil-,adőtt esetben szűbsztitűált aril- vagy adőtt esetben szűbsztitűáltaralkilcsőpőrt; A jelentése CH, C(OH) vagy nitrőgénatőm, X jelentésehidrőgén- vagy halőgénatőm vagy alkőxi-, vagy adőtt esetbenszűbsztitűált alkilcsőpőrt; és Q jelentése adőtt esetben szűbsztitűáltfenil-, adőtt esetben szűbsztitűált fenőxi-, adőtt esetbenszűbsztitűált fenilmetil- vagy adőtt esetben szűbsztitűáltciklőalkőxicsőpőrt, azzal a megkötéssel, hőgy ha E1 jelentése őxigén-vagy kénatőm, akkőr E2 jelentése őxigén- vagy kénatőmtól eltérő. Atalálmány szerinti vegyületek példáűl ischémiás megbetegedésekbőladódó szimptómák enyhítésére és kezelésére alkalmasak. ŕ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30115497 | 1997-10-31 | ||
PCT/JP1998/004943 WO1999023072A1 (en) | 1997-10-31 | 1998-10-30 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0000719A2 true HUP0000719A2 (hu) | 2000-09-28 |
HUP0000719A3 HUP0000719A3 (en) | 2000-10-30 |
HU226767B1 HU226767B1 (en) | 2009-09-28 |
Family
ID=17893439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0000719A HU226767B1 (en) | 1997-10-31 | 1998-10-30 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
Country Status (14)
Country | Link |
---|---|
US (4) | US6407099B1 (hu) |
EP (2) | EP0958280B1 (hu) |
JP (2) | JP4036484B2 (hu) |
KR (2) | KR100795326B1 (hu) |
CN (1) | CN1157376C (hu) |
AT (2) | ATE294779T1 (hu) |
AU (1) | AU754656B2 (hu) |
CA (2) | CA2276373C (hu) |
DE (2) | DE69828317T2 (hu) |
DK (1) | DK0958280T3 (hu) |
ES (2) | ES2241169T3 (hu) |
HU (1) | HU226767B1 (hu) |
PT (1) | PT958280E (hu) |
WO (1) | WO1999023072A1 (hu) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119184B2 (en) * | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
CA2231879C (en) * | 1996-07-22 | 2007-01-23 | Suntory Limited | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same |
CA2276373C (en) * | 1997-10-31 | 2010-01-12 | Suntory Limited | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
GB9912416D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
US7074934B2 (en) * | 2000-06-13 | 2006-07-11 | Tularik Limited | Serine protease inhibitors |
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
WO2003039449A2 (en) * | 2001-11-07 | 2003-05-15 | Medical Research Council | Modulation of dopaminergic neurons |
GB0130696D0 (en) * | 2001-12-21 | 2002-02-06 | Smithkline Beecham Plc | Chemical Compounds |
US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
US7504431B2 (en) | 2004-04-16 | 2009-03-17 | Bristol-Myers Squibb Company | Sulfonyl amide inhibitors of calcium channel function |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
EP2054033A2 (en) * | 2006-07-31 | 2009-05-06 | Asubio Pharma Co., Ltd. | Liquid preparation |
WO2008026765A2 (en) * | 2006-08-30 | 2008-03-06 | Asubio Pharma Co., Ltd. | Lyophilized preparation |
CA2722776A1 (en) * | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
KR101476379B1 (ko) * | 2011-11-30 | 2014-12-29 | 한국과학기술연구원 | 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA967965A (en) * | 1968-12-24 | 1975-05-20 | Hoffmann-La Roche Limited | Aromatic ethers and process for the manufacture thereof |
GB1317034A (en) | 1970-11-06 | 1973-05-16 | Pfizer Ltd | 1-2-hydroxy-3-phenoxy- or -phenylthiopropyl-piperazine derivatives |
JPS5840551B2 (ja) | 1976-08-06 | 1983-09-06 | 田辺製薬株式会社 | プロパノ−ル誘導体及びその製法 |
JPS5321227A (en) | 1976-08-09 | 1978-02-27 | Chugoku Marine Paints | Production of soilproof paints |
JPS5697227A (en) | 1979-12-28 | 1981-08-05 | Tanabe Seiyaku Co Ltd | Intracranial hypotensor |
US4882330A (en) * | 1986-11-21 | 1989-11-21 | A. H. Robins Company, Incorporated | 1-aryloxy-4-[((4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents |
ES2004809A6 (es) * | 1987-07-29 | 1989-02-01 | Ferrer Int | Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas |
US5064838A (en) | 1988-01-21 | 1991-11-12 | Merrell Dow Pharmaceuticals | 1,4-disubstituted-piperidinyl compounds as pain relievers |
EP0576766A1 (en) | 1992-06-29 | 1994-01-05 | Novo Nordisk A/S | Propanolamine derivatives, their preparation and use |
TW275614B (hu) * | 1993-02-15 | 1996-05-11 | Senju Pharma Co | |
EP0622542B1 (de) | 1993-04-27 | 1996-08-28 | Siemens Aktiengesellschaft | Verbrennungsaussetzererkennung mit Schlechtwegerkennung |
EP0755923B1 (en) * | 1995-01-23 | 2005-05-04 | Daiichi Suntory Pharma Co., Ltd. | Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor |
HUP9602977A3 (en) * | 1995-02-28 | 1998-01-28 | Daiichi Asubio Pharma Co Ltd | Arylpiperidine and arylpiperazine derivatives and drugs containing the same |
DE69612698T2 (de) * | 1995-06-09 | 2001-12-06 | Hoffmann La Roche | Pyrimidindion-, Pyrimidintrion-, Triazindion-Derivate als alpha-1-adrenergische Rezeptorantagonisten |
HUT76265A (en) | 1995-10-19 | 1997-07-28 | Gyogyszerkutato Intezet | Pyrimidine derivatives, pharmaceutical compositions containing them, process for producing them and their use |
ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
US6313127B1 (en) * | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
WO1998003172A1 (fr) | 1996-07-22 | 1998-01-29 | Suntory Limited | Derives arylpiperidinol et arylpiperidine et medicaments les contenant |
CA2231879C (en) * | 1996-07-22 | 2007-01-23 | Suntory Limited | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same |
CA2276373C (en) * | 1997-10-31 | 2010-01-12 | Suntory Limited | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
-
1998
- 1998-10-30 CA CA002276373A patent/CA2276373C/en not_active Expired - Fee Related
- 1998-10-30 KR KR1020067003065A patent/KR100795326B1/ko not_active IP Right Cessation
- 1998-10-30 WO PCT/JP1998/004943 patent/WO1999023072A1/en active IP Right Grant
- 1998-10-30 DE DE69828317T patent/DE69828317T2/de not_active Expired - Lifetime
- 1998-10-30 AT AT98950482T patent/ATE294779T1/de active
- 1998-10-30 DK DK98950482T patent/DK0958280T3/da active
- 1998-10-30 CA CA002681877A patent/CA2681877A1/en not_active Abandoned
- 1998-10-30 EP EP98950482A patent/EP0958280B1/en not_active Expired - Lifetime
- 1998-10-30 DE DE69830045T patent/DE69830045T2/de not_active Expired - Lifetime
- 1998-10-30 ES ES98950482T patent/ES2241169T3/es not_active Expired - Lifetime
- 1998-10-30 PT PT98950482T patent/PT958280E/pt unknown
- 1998-10-30 CN CNB988021854A patent/CN1157376C/zh not_active Expired - Fee Related
- 1998-10-30 US US09/331,712 patent/US6407099B1/en not_active Expired - Fee Related
- 1998-10-30 HU HU0000719A patent/HU226767B1/hu not_active IP Right Cessation
- 1998-10-30 AT AT01115281T patent/ATE285403T1/de not_active IP Right Cessation
- 1998-10-30 AU AU96516/98A patent/AU754656B2/en not_active Ceased
- 1998-10-30 KR KR1019997005955A patent/KR100599022B1/ko not_active IP Right Cessation
- 1998-10-30 ES ES01115281T patent/ES2230209T3/es not_active Expired - Lifetime
- 1998-10-30 JP JP52593199A patent/JP4036484B2/ja not_active Expired - Fee Related
- 1998-10-30 EP EP01115281A patent/EP1138678B1/en not_active Expired - Lifetime
-
2002
- 2002-04-09 US US10/118,045 patent/US6525199B1/en not_active Expired - Fee Related
- 2002-12-31 US US10/331,508 patent/US6838470B2/en not_active Expired - Fee Related
-
2004
- 2004-12-03 US US11/002,793 patent/US7642262B2/en not_active Expired - Fee Related
-
2007
- 2007-08-13 JP JP2007211113A patent/JP4785807B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0000719A2 (hu) | Aril-piperidino-propanol- és aril-piperazino-propanol-származékok, és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
HUP0300693A2 (hu) | Eljárás epotilon-analógok és -intermedierek előállítására | |
ES455294A1 (es) | Un procedimiento de preparacion de una fenilamidina sustituida. | |
ES330368A1 (es) | Procedimiento para preparar derivados n-alcohilamino-alcohilicos de espirotetralinosuccinimidas y sus sales. | |
ES269967A1 (es) | Un procedimiento para la preparaciën de pirazolonas sustituidas | |
ES393496A1 (es) | Procedimiento de preparacion de nuevos derivados de la 2-pi-rrolidinonas. | |
HUP0102031A2 (hu) | Széles spektrumú gombásodásgátló hatású vízoldható azolok, eljárás az előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
ES8101550A1 (es) | Un procedimiento para la preparacion de nuevos derivados de 2-pirrolidin-metanol. | |
IL72166A0 (en) | Beta-carboline derivatives and pharmaceutical compositions containing the same | |
MX9701734A (es) | Novedosos oxidos de acilfosfina. | |
ES417638A1 (es) | Procedimiento para preparar oxazoles 2,4,5-trisustituidos. | |
ES467069A1 (es) | Un procedimiento para la preparacion de nuevos derivados de 1-3-bencenodimetanol | |
HUP9801056A2 (hu) | Apolipoprotein-B szintézist gátló triazolonszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
ES423104A1 (es) | Procedimiento para preparar anilidas heterociclicas. | |
HUP9903526A2 (hu) | Pirimidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények | |
ES395766A1 (es) | Procedimiento para la obtencion de derivados de la hidan- toina. | |
ES441603A1 (es) | Procedimiento para preparar composiciones reguladoras del crecimiento de plantas. | |
ES393159A1 (es) | Procedimiento para la obtencion de compuestos heterocicli- cos de la serie piridona. | |
ES435351A1 (es) | Procedimiento para preparar 1-(3-fenil-propil)-4-furoilpi- perazinas. | |
ES441938A1 (es) | Procedimiento para la preparacion de nuevos arilisotiociana-tos. | |
ES389210A1 (es) | Procedimiento para la obtencion de fenoxi-aminas orto-sus- tituidas. | |
ES453121A1 (es) | Un metodo de preparacion de nuevos derivados de piridil u- reas. | |
ES485517A1 (es) | Un procedimiento para la obtencion de nuevos derivados hete-rociclicos de nitrogeno | |
ES439180A1 (es) | Procedimiento para la preparacion de derivados de piperido- na. | |
ES293050A1 (es) | Procedimiento para la fabricacion de nuevos derivados de 3-fenil-granaten-(2) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: ASUBIO PHARMA CO., LTD., JP Free format text: FORMER OWNER(S): DAIICHI ASUBIO PHARMA CO., LTD., JP; DAIICHI SUNTORY PHARMA CO., LTD., JP; SUNTORY LIMITED, JP |
|
MM4A | Lapse of definitive patent protection due to non-payment of fees |